Evolving fitness and immune escape: a retrospective analysis of SARS-CoV-2 spike protein (2020-2024) using protein language model

✅ 全文

适应性进化与免疫逃逸:基于蛋白质语言模型的SARS-CoV-2刺突蛋白回顾性分析(2020-2024)

作者 Sihua Peng; Leke Lyu; Ludy Registre Carmola; Sachin Subedi; M. H. M. Mubassir; Mohamed A Bakheet; Justin Bahl 期刊 Frontiers in Immunology 发表日期 2025 ISSN 1664-3224 DOI 10.3389/fimmu.2025.1576414 类型 原创研究 (Original Research)

📄 英文摘要 English Abstract

EN

Introduction: The COVID-19 pandemic posed global health challenges. Understanding SARS-CoV-2's evolutionary dynamics, especially fitness and immune escape, is vital for public health. This study uses protein language models to assess how genetic variations affect viral adaptability and immunity. Methods: We applied the CoVFit model to predict Fitness and Immune Escape Index (IEI), validated by a null model based on neutral evolution. We analyzed 2,504,278 SARS-CoV-2 spike sequences, including 160,892 variants, tracking evolution from 2020 to May 2024, comparing real and random mutants' Fitness and IEI. Results: Our analysis revealed an increase in Fitness (mean rising from 0.227 in 2020 to 0.930 in 2024) and IEI (mean increasing from 0.171 to 0.555) for North American samples. Globally, the comparison of Fitness and IEI between real and random mutants (generated by the null model) revealed statistically significant differences (real mutant Fitness 0.3849 vs. random mutant 0.2046, p < 0.001, KS test; real mutant IEI 0.2894 vs. random mutant 0.1895, p < 0.001, KS test), indicating strong selective pressure; the JN.1 lineage dominated (94% of sequences by April 2024), underscoring its evolutionary advantage. Conclusions: CoVFit offers key insights into SARS-CoV-2 evolution, aiding vaccine design. Persistent viral adaptation despite interventions highlights the need for surveillance and adaptive strategies using tools like CoVFit for preparedness.

📄 中文摘要 Chinese Abstract

中文
由SARS-CoV-2引起的COVID-19疫情构成了前所未有的全球性挑战。SARS-CoV-2是一种正义单链RNA病毒,其高突变率导致了大量变异株的出现,显著增强了其传播能力和免疫逃逸能力。尽管疫苗接种降低了重症率,但病毒的持续进化仍对疫苗策略构成挑战。SARS-CoV-2刺突(S)蛋白是决定其感染人类宿主能力的关键因素,通过与ACE2受体结合介导病毒进入细胞,并因其在介导病毒入侵和诱导中和抗体应答中的核心作用而成为大多数疫苗的主要靶点。病毒的进化轨迹受到免疫逃逸、环境压力和遗传变异等因素的深刻影响。因此,追踪S蛋白的适应性和免疫逃逸趋势对于开发新型疫苗和治疗策略至关重要。然而,传统分析方法难以全面捕捉其长期动态变化,需要借助先进的计算工具来阐明病毒进化模式。 蛋白质语言模型(PLMs)通过将氨基酸序列类比为句子,利用大规模序列数据捕捉蛋白质的生化特性,为研究病毒进化提供了新视角。在ESM-2等模型的基础上,Ito等人利用基因型-适应度数据和高通量深度突变扫描(DMS)实验数据对ESM-2进行微调,构建了CoVFit模型,绘制了SARS-CoV-2的适应度景观。本研究利用CoVFit模型,基于2024年1月1日至2024年5月15日期间收集的S蛋白序列,回顾性评估了2020年至2024年S蛋白的适应性和免疫逃逸趋势,旨在阐明突变如何随时间和地域塑造病毒特征。

📋 英文结构化总结 English Structured Summary

全文整理

EN

Background:

The COVID-19 pandemic, caused by SARS-CoV-2, has posed an unprecedented global challenge. SARS-CoV-2, a positive-sense single-stranded RNA virus, exhibits a high mutation rate that has led to the emergence of numerous variants, significantly enhancing its transmissibility and immune escape capabilities. Although vaccination has reduced severe disease rates, the virus’s ongoing evolution continues to challenge vaccine strategies. The SARS-CoV-2 spike (S) protein is a critical determinant of its ability to infect human hosts, facilitating viral entry by binding to ACE2 receptors, and serves as the primary target for most vaccines due to its pivotal role in mediating viral entry and eliciting neutralizing antibody responses. The evolutionary trajectory of the virus was profoundly shaped by factors such as immune evasion, environmental pressures, and genetic alterations. Consequently, tracking the fitness and immune escape trends of the S protein is essential for developing novel vaccines and therapeutic strategies. However, traditional analytical approaches struggled to comprehensively capture its long-term dynamics, necessitating advanced computational tools to elucidate the patterns of viral evolution.

Protein language models (PLMs) offer a novel perspective for studying viral evolution by treating amino acid sequences as analogous to sentences, leveraging large-scale sequence data to capture the biochemical properties of proteins. Building on advances such as ESM-2, Ito et al. fine-tuned ESM-2 using genotype-fitness data and high-throughput deep mutational scanning (DMS) experimental data to create CoVFit, mapping the fitness landscape of SARS-CoV-2. This study utilizes the CoVFit model, leveraging S protein sequences collected between January 1, 2024, and May 15, 2024, to retrospectively assess the fitness and immune escape trends of the S protein from 2020 to 2024. It aims to clarify how mutations have shaped viral characteristics across time and regions.

Methods:

We applied the CoVFit model to predict Fitness and Immune Escape Index (IEI), validated by a null model based on neutral evolution. We analyzed 2,504,278 SARS-CoV-2 spike sequences, including 160,892 variants, tracking evolution from 2020 to May 2024, comparing real and random mutants’ Fitness and IEI.

Results:

Our analysis revealed an increase in Fitness (mean rising from 0.227 in 2020 to 0.930 in 2024) and IEI (mean increasing from 0.171 to 0.555) for North American samples. Globally, the comparison of Fitness and IEI between real and random mutants (generated by the null model) revealed statistically significant differences (real mutant Fitness 0.3849 vs. random mutant 0.2046, p < 0.001, KS test; real mutant IEI 0.2894 vs. random mutant 0.1895, p < 0.001, KS test), indicating strong selective pressure; the JN.1 lineage dominated (94% of sequences by April 2024), underscoring its evolutionary advantage.

Data Summary:

For North American samples, mean Fitness rose from 0.227 in 2020 to 0.930 in 2024, and mean IEI increased from 0.171 to 0.555. Globally, real mutant Fitness (0.3849) and IEI (0.2894) were significantly higher than random mutant values (0.2046 and 0.1895, respectively; both p < 0.001, KS test). By April 2024, the JN.1 lineage comprised 94% of sequences. The dataset included 2,504,278 SARS-CoV-2 spike sequences and 160,892 variants.

Conclusions:

CoVFit offers key insights into SARS-CoV-2 evolution, aiding vaccine design. Persistent viral adaptation despite interventions highlights the need for surveillance and adaptive strategies using tools like CoVFit for preparedness. This systematic analysis addresses the shortcomings of previous research, offering new scientific insights for predicting future variants and optimizing public health strategies.

Practical Significance:

CoVFit aids vaccine design and highlights the need for surveillance and adaptive strategies to prepare for persistent viral adaptation despite interventions. The model provides a tool to track evolutionary dynamics, supporting the optimization of public health strategies and informing the development of novel vaccines and therapeutic approaches.

📋 中文结构化总结 Chinese Structured Summary

中文

背景:

由SARS-CoV-2引起的COVID-19疫情构成了前所未有的全球性挑战。SARS-CoV-2是一种正义单链RNA病毒,其高突变率导致了大量变异株的出现,显著增强了其传播能力和免疫逃逸能力。尽管疫苗接种降低了重症率,但病毒的持续进化仍对疫苗策略构成挑战。SARS-CoV-2刺突(S)蛋白是决定其感染人类宿主能力的关键因素,通过与ACE2受体结合介导病毒进入细胞,并因其在介导病毒入侵和诱导中和抗体应答中的核心作用而成为大多数疫苗的主要靶点。病毒的进化轨迹受到免疫逃逸、环境压力和遗传变异等因素的深刻影响。因此,追踪S蛋白的适应性和免疫逃逸趋势对于开发新型疫苗和治疗策略至关重要。然而,传统分析方法难以全面捕捉其长期动态变化,需要借助先进的计算工具来阐明病毒进化模式。

蛋白质语言模型(PLMs)通过将氨基酸序列类比为句子,利用大规模序列数据捕捉蛋白质的生化特性,为研究病毒进化提供了新视角。在ESM-2等模型的基础上,Ito等人利用基因型-适应度数据和高通量深度突变扫描(DMS)实验数据对ESM-2进行微调,构建了CoVFit模型,绘制了SARS-CoV-2的适应度景观。本研究利用CoVFit模型,基于2024年1月1日至2024年5月15日期间收集的S蛋白序列,回顾性评估了2020年至2024年S蛋白的适应性和免疫逃逸趋势,旨在阐明突变如何随时间和地域塑造病毒特征。

方法:

我们应用CoVFit模型预测适应性和免疫逃逸指数(IEI),并通过基于中性进化的零模型进行验证。我们分析了2,504,278条SARS-CoV-2刺突序列,包括160,892个变异株,追踪了从2020年至2024年5月的进化过程,比较了真实突变体与随机突变体的适应性和IEI。

结果:

我们的分析显示,北美样本的适应性(均值从2020年的0.227上升至2024年的0.930)和IEI(均值从0.171上升至0.555)均呈上升趋势。在全球范围内,真实突变体与随机突变体(由零模型生成)的适应性和IEI比较显示统计学显著差异(真实突变体适应性0.3849 vs. 随机突变体0.2046,p < 0.001,KS检验;真实突变体IEI 0.2894 vs. 随机突变体0.1895,p < 0.001,KS检验),表明存在强烈的选择压力;JN.1谱系占据主导地位(截至2024年4月占序列的94%),凸显了其进化优势。

数据摘要:

对于北美样本,平均适应性从2020年的0.227上升至2024年的0.930,平均IEI从0.171上升至0.555。在全球范围内,真实突变体的适应性(0.3849)和IEI(0.2894)显著高于随机突变体的对应值(分别为0.2046和0.1895;两者p < 0.001,KS检验)。截至2024年4月,JN.1谱系占序列的94%。数据集包含2,504,278条SARS-CoV-2刺突序列和160,892个变异株。

结论:

CoVFit为理解SARS-CoV-2进化提供了关键见解,有助于疫苗设计。尽管采取了干预措施,病毒的持续适应性进化凸显了利用CoVFit等工具进行监测和制定适应性策略的必要性。本系统性分析弥补了以往研究的不足,为预测未来变异株和优化公共卫生策略提供了新的科学见解。

实际意义:

CoVFit有助于疫苗设计,并强调了在干预措施下仍需进行监测和制定适应性策略以应对病毒持续进化的必要性。该模型为追踪进化动态提供了工具,支持公共卫生策略的优化,并为开发新型疫苗和治疗方案提供参考依据。

📖 英文全文 English Full Text

EN

TYPE Original Research PUBLISHED 18 June 2025 DOI 10.3389/fimmu.2025.1576414 OPEN ACCESS EDITED BY Maolin Lu, University of Texas at Tyler Health Science Center, United States REVIEWED BY

Arvind Ramanathan, Argonne National Laboratory (DOE), United States Md. Aminul Islam, Tulane University, United States *CORRESPONDENCE

Justin Bahl justin.bahl@uga.edu Sihua Peng Sihua.Peng@uga.edu RECEIVED 13 February 2025 ACCEPTED 30 May 2025

Evolving fitness and immune escape: a retrospective analysis of SARS-CoV-2 spike protein (2020-2024) using protein language model Sihua Peng 1,2*, Leke Lyu 1,3, Ludy Registre Carmola 2, Sachin Subedi 1,2,3, M. H. M. Mubassir 1,2,3, Mohamed A. Bakheet 1,2 and Justin Bahl 1,2,3,4* Center for Ecology of Infectious Diseases, University of Georgia, Athens, GA, United States, Department of Infectious Diseases, University of Georgia, Athens, GA, United States, 3 Institute of Bioinformatics, University of Georgia, Athens, GA, United States, 4 Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, United States 1

Peng S, Lyu L, Carmola LR, Subedi S, Mubassir MHM, Bakheet MA and Bahl J (2025) Evolving fitness and immune escape: a retrospective analysis of SARS-CoV-2 spike protein (2020-2024) using protein language model. Front. Immunol. 16:1576414. doi: 10.3389/fimmu.2025.1576414 COPYRIGHT

© 2025 Peng, Lyu, Carmola, Subedi, Mubassir, Bakheet and Bahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Introduction: The COVID-19 pandemic posed global health challenges. Understanding SARS-CoV-2’s evolutionary dynamics, especially fitness and immune escape, is vital for public health. This study uses protein language models to assess how genetic variations affect viral adaptability and immunity. Methods: We applied the CoVFit model to predict Fitness and Immune Escape Index (IEI), validated by a null model based on neutral evolution. We analyzed 2,504,278 SARS-CoV-2 spike sequences, including 160,892 variants, tracking evolution from 2020 to May 2024, comparing real and random mutants’ Fitness and IEI. Results: Our analysis revealed an increase in Fitness (mean rising from 0.227 in 2020 to 0.930 in 2024) and IEI (mean increasing from 0.171 to 0.555) for North American samples. Globally, the comparison of Fitness and IEI between real and random mutants (generated by the null model) revealed statistically significant differences (real mutant Fitness 0.3849 vs. random mutant 0.2046, p < 0.001, KS test; real mutant IEI 0.2894 vs. random mutant 0.1895, p < 0.001, KS test), indicating strong selective pressure; the JN.1 lineage dominated (94% of sequences by April 2024), underscoring its evolutionary advantage. Conclusions: CoVFit offers key insights into SARS-CoV-2 evolution, aiding vaccine design. Persistent viral adaptation despite interventions highlights the need for surveillance and adaptive strategies using tools like CoVFit for preparedness.

SARS-CoV-2, spike protein, protein language models, protein fitness, immune escape, retrospective analysis Frontiers in Immunology 01 frontiersin.org Peng et al. 10.3389/fimmu.2025.1576414

they predominantly focus on specific variants or short-term trends and often rely on statistical models that overlook mutation interactions (27–29), failing to provide a global analysis of S protein dynamics throughout the pandemic. Prior studies, such as Islam et al. (30) on XBB.1.5 immune escape and Hasan et al. (31) on vaccine efficacy and meteorological factors, have explored SARS-CoV-2 evolution. However, these efforts primarily focused on specific variants or short-term regional trends and did not address the long-term global dynamics of the S protein from 2020 to 2024. This study utilizes the CoVFit model, leveraging S protein sequences collected between January 1, 2024, and May 15, 2024, to retrospectively assess the fitness and immune escape trends of the S protein from 2020 to 2024. It aims to clarify how mutations have shaped viral characteristics across time and regions. This systematic analysis addresses the shortcomings of previous research, offering new scientific insights for predicting future variants and optimizing public health strategies.

1 Introduction The COVID-19 pandemic, caused by SARS-CoV-2, has posed an unprecedented global challenge (1). SARS-CoV-2, a positive-sense single-stranded RNA virus, exhibits a high mutation rate that has led to the emergence of numerous variants, significantly enhancing its transmissibility and immune escape capabilities (2–4). Although vaccination has reduced severe disease rates, the virus’s ongoing evolution continues to challenge vaccine strategies (5, 6). The SARSCoV-2 spike (S) protein is a critical determinant of its ability to infect human hosts, facilitating viral entry by binding to ACE2 receptors (7), and serves as the primary target for most vaccines due to its pivotal role in mediating viral entry and eliciting neutralizing antibody responses (8–10). The evolutionary trajectory of the virus was profoundly shaped by factors such as immune evasion, environmental pressures, and genetic alterations (2–5). Consequently, tracking the fitness and immune escape trends of the S protein is essential for developing novel vaccines and therapeutic strategies. However, traditional analytical approaches struggled to comprehensively capture its longterm dynamics, necessitating advanced computational tools to elucidate the patterns of viral evolution. Protein language models (PLMs) offer a novel perspective for studying viral evolution by treating amino acid sequences as analogous to sentences, leveraging large-scale sequence data to capture the biochemical properties of proteins (11). The advent of transformer architectures has marked a significant advancement in predictive capabilities (12). For instance, Rao et al. pioneered the application of BERT to protein prediction with the TAPE model (13), Elnaggar et al. expanded its utility across diverse protein families with ProtTrans (14), and Rives et al. enhanced downstream task performance with ESM-1b, trained on the UniProt database (15). Building on these advances, Lin et al. developed ESM-2, a model with 1.5 billion parameters capable of directly inferring protein structures (16), while Ito et al. fine-tuned ESM-2 using genotype-fitness data and high-throughput deep mutational scanning (DMS) experimental data (17, 18) to create CoVFit, mapping the fitness landscape of SARS-CoV-2 (19). DMS, integrating deep sequencing with systematic mutation analysis, provides robust support for assessing the immune escape potential of the S protein (20, 21). Recently, PLMs have gained prominence in SARS-CoV-2 evolutionary research. Ma et al. devised a deep learning model combining regularity and stochasticity to predict viral evolution, validating several highly transmissible variants, though its 5,000epoch training may risk overfitting (22). Lamb et al. trained a model on 65 million protein sequences using ESM-2 to uncover evolutionary potential, yet it lacks domain-specific fine-tuning (23). King et al. developed the VPRE model to forecast future variants with limited data, but its reliance on 20,000 synthetic sequences may introduce artefactual features (24). Elkin et al. proposed the DNMS approach to predict novel S protein mutations, limited to single amino acid substitutions (25). Zvyagin et al. employed the GenSLM model to simulate viral dynamics, constrained by a smaller training dataset (26). While these studies demonstrate the potential of PLMs, Frontiers in Immunology

2 Materials and methods The pipeline of this study is shown in Figure 1, with data derived from global SARS-CoV-2 S protein sequences collected from January 2020 to May 2024.

2.1 Data collection A total of 2,504,278 SARS-CoV-2 S protein sequences, collected between January 1, 2020 and May 15, 2024, were downloaded from NCBI SARS-CoV-2 Data Hub. The sequences were divided into 18 segments of three-month intervals to analyze the evolutionary trajectory of SARS-CoV-2 fitness and immune evasion (https:// www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_ s=Nucleotide&VirusLineage_ss=taxid:2697049). Sequences containing more than five unidentified characters were excluded from the analysis.

2.2 Variant sequence identification and mutation count In the epidemiology of SARS-CoV-2, the terms “mutation,” “variant,” and “strain” are often used interchangeably, but they have distinct scientific meanings. A protein mutation refers to an actual change in the protein sequence, such as D614G, which is the substitution of aspartic acid for glycine at position 614 of the spike protein (32). Genomes differing in sequence are typically referred to as variants. This term can be vague since two variants might differ by one or many mutations. A variant is considered a strain when it exhibits a significantly different phenotype, such as differences in antigenicity, transmissibility, or virulence (33, 34). In this study, we define “variants” as spike protein S amino acid

collapse short branches into polytomies. The patristic distances between all tips and the root of the tree were calculated using the ape package in R (37). We plotted the patristic distances against sampling dates to estimate the molecular clock rate.

sequences that differ by one or more mutations. Some of these variants may not show differences in antigenicity, transmissibility, or virulence, but any two variants referred to in this text do differ in their amino acid sequences, commonly termed variant sequences or simply as variants. The downloaded S protein data over various time periods contained many duplicate sequences. Duplicate sequences within each of the 18 time periods were removed, resulting in unique amino acid sequences, henceforth referred to as “variants”, within each time period. A total of 160,892 variants were obtained (Supplementary Table S1). However, some samples might be duplicated across different time periods. The positions and frequencies of mutations varied for each variant. To study the changes in mutation frequency over time, we calculated the frequency of mutations in each variant sequence. A cubic spline interpolation was used to connect the mean values of mutation counts for each time segment. The code developed to remove duplications, and count occurrence and frequency of mutations is available at https://github.com/pengsihua2023/SARSCoV-2-Fitness-IEI.

2.4 Fitness values analysis Ito et al. first established the ESM-2 Coronaviridae model (19) by pre-training (i.e., domain adaptation) on S protein sequences obtained from 1,506 types of coronaviruses. Then, they fine-tuned the model on genotype–fitness (Re) data and DMS data to evaluate antibody neutralization escape capabilities. Consequently, for a given S protein sequence, CoVFit can predict the Fitness value in a specific country and its ability to escape from each monoclonal antibody (mAb). Their dataset included data from 17 countries: Australia, Belgium, Brazil, Canada, Denmark, France, Germany, India, Italy, Japan, the Netherlands, South Korea, Spain, Sweden, Switzerland, the United Kingdom, and the United States. CoVFit model (https:// github.com/TheSatoLab/CoVFit) was finetuned from ESM-2 protein model using two data sets: i) genotype–fitness data obtained from virus genome surveillance and ii) mutation effect data on evasion ability from humoral immunity, determined by high-throughput deep mutational scanning (DMS) experiments. Then, using a multinomial logistic model fitted to genome surveillance data from the Global Initiative on Sharing All Influenza Data (GISAID) up to November 2, 2023, the Effective Reproduction Number (Re) of each genotype in each country was estimated. Re is an epidemiological parameter used to measure the transmission potential of an infectious disease within a specific population (38, 39). As a result, 21,751 genotype-fitness data points were

2.3 Phylogenetic and molecular clock analysis We collected global S protein sequences sampled between 2020 and 2024. A random subset of 5,000 sequences with detailed sampling dates was selected. Sequences were aligned against the Wuhan-Hu-1 reference genome using MAFFT V 7.520 (35). Phylogenetic trees were inferred using IQ-TREE V 2.2.2.6 (36) with the LG+I+G substitution model, applying the -czb flag to

FIGURE 1

Pipeline for retrospective analysis of SARS-CoV-2 spike protein Fitness and Immune Escape (2020–2024) using CoVFit. This figure illustrates the workflow for analyzing the Fitness and immune escape index (IEI) of SARS-CoV-2 spike (S) protein variants using the CoVFit model. The pipeline first performs domain adaptation finetuning of the pretrained ESM-2 model using various coronavirus data, followed by a second finetuning step with SARS-CoV-2 data, and finally predicts the Fitness and IEI of historical SARS-CoV-2 data. The components are as follows: (A) Protein Sequence Data – Sequences from eukaryotes, bacteria, archaea, and viruses, used for pretraining ESM-2 (650M) model; (B) ESM-2 – A pretrained protein language model for learning general protein representations; (C) S Protein Variants – SARS-CoV-2 spike protein sequences collected from January 2020 to May 2024; (D) Fitness Prediction – Prediction of Fitness of S protein variants; (E) Protein Sequence Data (Coronavirus) – Sequences from different coronavirus species, used for domain adaptation finetuning of ESM-2; (F) ESM-2 (Coronavirus Finetuned) – ESM-2 model finetuned on coronavirus sequences for SARS-CoV-2-specific tasks; (G) CoVFit – A finetuned model supporting multiple tasks, including fitness and immune escape prediction; and (H) Immune Escape Index Prediction – Immune escape capability based on relative binding affinity to 1,548 monoclonal antibodies (mAbs).

the null model aims to assess whether the observed results significantly deviate from neutral evolution expectations, thereby demonstrating the reliability of the computational outcomes. The null model is designed based on seven datasets, covering six continents (Africa, Asia, Europe, North America, Oceania, and South America) and an overall dataset (combining all six continents).

obtained, covering 12,914 genotypes across the 17 countries, indicating that the fitness of S protein originally derived from publicly available data set of, which (38, 39) Finally, the derived fitness data were scaled to 0–1 for the convenience of model training (38, 39). We adopted the CoVFit protein model for this study to analyze the temporal trends in Fitness and Immune Escape Indices (IEI) and the geographical distribution of SARS-CoV-2 variants across different continents. Model files were downloaded from Zenodo (https://zenodo.org/records/10911205). We used Clustal Omega1.2.3 (40) to perform multiple sequence alignment of the amino acid sequences and input the aligned S protein sequences into the CoVFit model to predict the Fitness value of the S protein. The average Fitness value for North America was derived as the average of the United States and Canada. For Europe, the average was derived from Germany, the United Kingdom, Switzerland, Sweden, Spain, the Netherlands, Italy, France, Denmark, and Belgium. The average of South Korea, Japan, and India represent was used for Asia. The Fitness value of Australia was regarded as the average for Oceania, and the Fitness value of Brazil was regarded as the average for South America. Since the number of genotypes from Africa did not exceed 300, the CoVFit model did not include data from African countries during training. Consequently, there are no Fitness prediction values for Africa. For the sake of completeness, the average Fitness prediction values of the 17 countries were used as the Fitness average for Africa. Therefore, when using CoVFit for model predictions, the S protein sequence data from Africa was input, and the average Fitness values of the 17 countries were used as the Fitness average for Africa. Fitness values were also calculated for recent prevalent variants in North America. A total of 2,170 S protein amino acid sequences, with 543 variants, collected between April 1, 2024, and May 15, 2024 were utilized for the analysis.

2.6.1 Generation of random sequences under neutral evolution The null model simulates the evolution of the S protein under neutral evolutionary conditions (unaffected by selection pressures from the host immune system, vaccination, or environmental factors), reflecting the accumulation of random mutations. This provides a statistical baseline to validate the Fitness/IEI of real sequences and the random mutatant sequence. Using the WuhanHu-1 sequence (GenBank: MN908947.3, 1,273 amino acids) as a template, and based on the amino acid substitution rate from Figure 2B (25.9223 substitutions/year), neutral drift over 4.375 years (January 2020 to May 2024) is simulated through uniformly random mutation at each position.

2.6.2 Calibration of evolutionary parameters To reflect real evolutionary dynamics, key parameters are determined through the following steps: Time Span: The simulation duration is set to 4.375 years, corresponding to the time window of this study; Mutation Rate Calculation: Based on observed data, the S protein accumulates an average of 25.9223 amino acid mutations over 4.375 years, from which the per-site annual mutation rate is calculated: m=

Where Nmut is the total number of mutations per year, and L is the sequence length. Through literature review, we found the proportion of neutral mutations in the S protein: approximately 10-30% overall, <10% in the RBD, and 20-40% in the non-RBD regions (2, 20, 27, 41, 42). Neutral Proportion: Set 20% of mutations as driven by neutral evolution, adjusting the effective mutation rate to mnertral =m×0.2; Branch Length: The theoretical branch length is calculated as mnertral  T, resulting in 0.0178.

2.5 Immune escape index The CoVFit model can predict the relative binding affinities of different monoclonal antibodies (mAbs). By inputting a SARS-CoV-2 S protein sequence, the model can predict the relative binding affinities for 1,548 mAbs. We averaged these predicted affinity values and denoted the average as the IEI, which describes the immune escape capability of a variant. The higher the IEI, the greater the immune escape capability of the variant. IEI was calculated for the Global and North American dataset described in the prior section.

2.6.3 Evolutionary model configuration Substitution Model: WAG amino acid substitution matrix (Whelan-And-Goldman model); Phylogenetic Tree: Construct a parsimonious evolutionary tree; Neutral Constraint: Set dN/dS = 1, retaining only neutral mutations.

2.6 Constructing a null model for benchmark comparison of fitness and immune escape 2.6.4 Variant generation

To verify the statistical robustness of the Fitness and immune escape index (IEI) predictions for SARS-CoV-2 S protein sequences, we developed a null model that generates random sequences as a neutral evolution baseline. By comparing random data with real data, Frontiers in Immunology

Nmut 25:9223 = 0:02036 Mutation=site=year = 1273 L

Perform N independent evolutionary simulations (e.g., 2,604 times, corresponding to a typical sampling scale in South America), with each simulation generating variants through the following steps: 04

frontiersin.org Peng et al. 10.3389/fimmu.2025.1576414 FIGURE 2 (A) Phylogenetic tree of a random subset of 5,000 global SARS-CoV-2 S protein sequences (sourced from NCBI SARS-CoV-2 Data Hub, 2020– 2024), constructed using IQ-TREE v2.2.2.6 with the LG+I+G substitution model and the -czb flag to collapse short branches. The scale bar represents a genetic distance of 0.007 substitutions per site. (B) Scatter plot of patristic distances (calculated using the R package ape) versus sampling dates for the same 5,000 S protein sequences, aligned against the Wuhan-Hu-1 reference genome using MAFFT v7.520. Each point represents a sequence, with patristic distance measured as substitutions from the reference. The red dashed line shows the linear regression with a molecular clock rate of 25.9223 substitutions/year (R² = 0.6789).

date 2020-01-20, 66 mutations) and WIJ15993.1 (reported date 202002-02, 42 mutations) were inconsistent with the typical mutation counts of the same period (usually <10 (5)), suggesting potential date errors. To assess their impact, we removed these two samples (accounting for 0.0014% of the 140,000 variants in North America) and recalculated the molecular clock rate, as well as the mean Fitness and IEI values for North America.

- Use the Evolver module in Pyvolve (43) to evolve sequences along the specified phylogenetic tree; - Randomly introduce mutations conforming to neutral constraints via a Poisson process; - Record the final mutated sequences and save them in FASTA format. The code for generating random mutation sequences can be found at: https://github.com/pengsihua2023/SARS-CoV-2-Fitness-IEI/ tree/main/code

2.8 Prediction study on the fitness and immune escape of the S protein in recent prevalent variants in North America 2.6.5 Kolmogorov-Smirnov test for assessing deviation of real variants from neutral evolution

A total of 2,170 S protein amino acid sequences, with 543 variants, were downloaded from the United States between April 1, 2024, and May 15, 2024. We then conducted a prediction study on the fitness and immune escape capabilities of all the variants’ S proteins. It should be noted that the downloaded U.S. samples actually represent the sample size for all of North America.

We employed the CoVFit model to predict Fitness and Immune Escape Index (IEI) values for randomly generated variants, establishing an expected distribution under neutral evolution. Subsequently, we applied the Kolmogorov-Smirnov (KS) test (p < 0.05) to compare the distributions of real SARS-CoV-2 spike protein variants with those of the random variants, evaluating whether the observed evolutionary patterns significantly deviate from neutral expectations.

2.9 Global retrospective analysis of S protein fitness and immune escape 2.7 Outlier metadata verification and sensitivity analysis

We divided the time periods into three-month intervals and downloaded the S protein data for six continents from January 1, 2020, to May 15, 2024, removing duplicate sequences from the same time-period. We then conducted retrospective studies on the fitness and immune escape capabilities of the S proteins for each period and continent.

To verify the metadata of two extreme outliers in North America (WZD59850.1 and WIJ15993.1), we examined their collection dates through the NCBI SARS-CoV-2 Data Hub. WZD59850.1 (reported Frontiers in Immunology

05 frontiersin.org Peng et al. 10.3389/fimmu.2025.1576414 (Supplementary Table S2). We found that the JN.1 lineage had the highest number of variants (n=1,082) while JN.1.7.2 had the fewest, with only 10 variants. In some lineages, there was an obvious difference between the Fitness and IEI of different variants. For example, the highest Fitness for JN.1.16 was 0.914, and the lowest was 0.863 (Supplementary Table S2). In summary, we identified the top 20 variants as notable concerns in North America, with XAN64366.1 (JN.1.16 lineage) being the most significant due to its high Fitness (0.925) and IEI (0.585) values.

3 Results 3.1 Prediction study in America: January 1, 2024, to May 15, 2024 The CoVFit model was used to predict the Fitness and IEI values for the 543 variants in the United States, and the top 20 highest Fitness values were displayed in Table 1. The higher the Fitness value, the greater the transmission potential of the variant. The case with the highest Fitness value was from an Iowa case. The difference in Fitness values among these 20 variants was small, ranging from 0.921 to 0.925, and the differences in IEI were also minor, ranging from 0.581 to 0.589. Of these 20 variants, 11 lineages of SARS-CoV-2 are included. For example, lineages JN.1.16, JN.1.11.1, and JN.1.7 each had three variants included in the top 20 (Table 1). indicating that different numbers of mutations can lead to different Fitness values. This may be because different amino acid mutations may significantly alter the protein conformation, affecting the binding affinity of the S protein to the human ACE2 receptor. We then conducted a historical examination of the 11 lineages, identifying all global S protein variants from 2020 to 2024

3.2 Retrospective study from January 1, 2020 to May 15, 2024 We analyzed the distribution of lineages and mutations within the variants, and identified the dominant lineage, mean mutations per variant, maximum and minimum of Fitness, and IEI for the variants, as well as its percentage among all lineages during each specific time period. Among the six continents, North America accounted for 95.46% of the cases and 89.66% of the variants. Therefore, we primarily present the analysis results for North America here (Table 2). The results of the other five continents are provided in the supplementary material (Supplementary Tables S3–S7).

TABLE 1 Top 20 predicted Fitness values and IEI for SARS-CoV-2 variants in the United States. Variant Accession # Lineage XAN64366.1 JN.1.16 2024-04-29 0.925 0.585 XBA97060.1 JN.1.11.1 2024-05-09 0.924

0.584 XAW33708.1 JN.1.16 2024-05-06 0.924 0.584 XAU78949.1 JN.1.11.1 2024-04-20 0.924 0.584 XAU78842.1 JN.1.7 2024-04-17 0.923 0.584 XAJ36120.1 JN.1.11.1 2024-04-21 0.923 0.584 XAW33862.1 JN.1.4.2 2024-04-29

0.923 0.586 XAJ04662.1 JN.1.9 2024-04-10 0.923 0.585 XAN64414.1 JN.1 2024-04-25 0.922 0.589 XAW33674.1 BA.2.86.1 2024-05-04 0.922 0.589 XAO61989.1 JN.1 2024-04-02 0.922 0.581 XAJ04710.1 XDD 2024-04-14

0.922 0.588 XAU78878.1 JN.1.9 2024-04-24 0.921 0.588 WZH70794.1 JN.1.16 2024-04-08 0.921 0.581 XBA97012.1 JN.1.7.2 2024-04-30 0.921 0.588 XAW19132.1 JN.1.8.1 2024-04-17 0.921 0.588 XAJ29041.1 JN.1.7 2024-04-16

0.921 0.588 XAU78770.1 JN.1.7 2024-04-05 0.921 0.588 XAU78782.1 JN.1.4 2024-04-03 0.921 0.588 XAU78794.1 JN.1.4 2024-04-03 0.921 0.588 Frontiers in Immunology Collection date Fitness 3.2.1 Unveiling the high evolutionary rate of the S protein

IEI

The phylogenetic tree (Figure 2A) illustrates distinct clusters and branching patterns, which are likely to correspond to different geographic regions or temporal clusters. This comprehensive phylogenetic analysis offers critical insights into the evolutionary dynamics of SARS-CoV-2 spike protein, enhancing our understanding of its proliferation and mutation over time. Figure 2B shows that the molecular clock estimation reveals a substitution rate of approximately 25.9223 substitutions per year, indicating a high evolutionary rate for the S protein sequences sampled globally between 2020 and 2024. The scatter plot (Figure 2B) displays a general trend where patristic distances increase over time, fitting well with the estimated molecular clock rate (R² = 0.6789), suggesting a consistent rate of evolution across the observed period.

3.2.2 Evolution of mutations in S protein variant sequences We found that the distribution of the number of mutations per variant during the entire SARS-CoV-2 pandemic could be divided into three distinct stages (Figure 3A, Supplementary Figures S1–S5). In North America, the first stage, spanning approximately from January 2020 to December 2021, marks a phase of rapid viral mutation. We observed a large number of outliers, representing sequences with extremely high numbers of mutations. During the middle stage of the pandemic, from January 2022 to March 2023, the total number of mutations continued to increase, however the number of outliers above the median decreased, indicating a slowdown in the rate of rapid mutations. This stage also recorded

TABLE 2 Profiles of SARS-Cov-2 variants in North America: lineage, mutation, fitness, and IEIs. Time Period Case/ Variant sequence Dominant Lineage Dominant Percentage Unique Lineages MMut MaxFit MFit MaxIEI

MIEI Jan-Mar, 2020 10,055/400 B.1 37.5% 73 2 0.963 0.227 0.591 0.171 Apr-Jun, 2020 19,662/968 B.1 35.85% 154 2 0.325 0.211 0.373 0.164 Jul-Sep, 2020 18,434/1,159 B.1 16.65% 169 2 0.329 0.212 0.513 0.164

Oct-Dec, 2020 45,478/3,264 B.1.2 30.91% 213 3 0.531 0.229 0.384 0.196 Jan-Mar, 2021 140,838/10,916 B.1.2 25.53% 283 6 0.534 0.286 0.466 0.258 Apr-Jun, 2021 177,356/11,233 B.1.1.7 39.6% 220 14 0.534 0.286

0.442 0.297 Jul-Sep, 2021 382,456/21,392 AY.44 11.53% 203 20 0.645 0.363 0.372 0.254 Oct-Dec, 2021 461,734/25,974 AY.103 17.9% 210 28 0.694 0.421 0.387 0.275 Jan-Mar, 2022 247,674/9,632 BA.1.1 39.11% 185

49 0.773 0.527 0.436 0.313 Apr-Jun, 2022 261,252/8,397 BA.2.12.1 31.19% 240 39 0.795 0.642 0.451 0.367 Jul-Sep, 2022 253,298/11,225 BA.5.2.1 12.71% 390 40 0.806 0.715 0.459 0.398 Oct-Dec, 2022 147,966/11,044

BQ.1.1 8.82% 626 42 0.837 0.755 0.476 0.424 Jan-Mar, 2023 90,796/8,895 XBB.1.5 23.66% 706 53 0.891 0.780 0.518 0.441 Apr-Jun, 2023 22,424/3,707 XBB.1.5 27.65% 562 50 0.901 0.808 0.532 0.459 Jul-Sep, 2023

38,369/5,797 FL.1.5.1 5.49% 629 64 0.911 0.857 0.532 0.489 Oct-Dec, 2023 44,399/6,486 HV.1 14.75% 534 63 0.924 0.895 0.551 0.522 Jan-Mar, 2024 26,275/3,216 JN.1 27.92% 247 72 0.913 0.901 0.545 0.536 Apr-May, 2024

2,170/543 JN.1 15.65 46 68 0.940 0.930 0.563 0.555

MMut, Mean Mutation; MaxFit, Maximum Fitness; MFit, Mean Fitness; MaxIEI, Maximum Immune Escape Index; MIEI, Mean Immune Escape Index.

relatively low lineage counts with minimal fluctuations, which might be due to fewer sequencing samples from these regions (Figure 3B). Overall, the lineage counts in North America are significantly higher than those in other continents, with three notable peaks, reflecting differences in viral surveillance and sequencing sample sizes across regions.

a substantial number of mutations below the median, suggesting that cases with fewer mutations from the earlier stage persisted. In the third stage, from April 2023 onward, the number of outliers, both those with fewer and those with a large number of mutations, significantly decreased, signaling a potential winding down of the pandemic (Figure 3A). Similar patterns were observed for the other five continents (Supplementary Figures S1–S5).

3.2.4 Comparison with Null model: Trends in fitness and immune escape 3.2.3 Evolution of global SARS-CoV-2 lineage numbers over various time periods

To contextualize the evolutionary trends of SARS-CoV-2 spike (S) protein sequences, we compared the Fitness and immune escape index (IEI) values of real sequences with those of random sequences generated based on a null model (see Section 2.6 for the methodology assumed for null model generation). The null model simulates neutral evolution by generating sequences with random mutations, providing a baseline to assess whether observed trends are driven by selective pressure or could arise randomly. Globally, the distribution of Fitness values for real sequences (mean = 0.3849) differed significantly from that of random sequences (mean = 0.2046) (p < 0.001, KS test) (Supplementary Table S8). Similarly, the distribution of IEI values for real sequences (mean = 0.2894) showed a significant difference compared to random sequences (mean = 0.1895) (p < 0.001, KS test) (Supplementary Table S9). These results indicate that the Fitness and IEI values observed globally are substantially higher than expected under neutral evolution, suggesting that these traits may

Among the global dataset, 2,442 lineages were represented. The lineage counts in North America were consistently higher than those in other continents throughout the observed period (Figure 3B). This pronounced difference is likely attributable to the larger number of samples sequenced in North America, leading to the detection of more lineages. Specifically, the lineage counts in North America exhibit three distinct peaks: The first peak occurred at the end of 2021, reaching a notable high; the second peak was observed at the end of 2022, again showing significant growth; and the third peak emerged around September 2023, indicating a third substantial increase. In contrast, the lineage counts in other continents remained relatively stable over time. For instance: Europe and Asia showed relatively stable lineage counts throughout the period, with only minor fluctuations and no significant peaks comparable to those in North America; and Africa, Oceania, and South America exhibit

(A) Temporal analysis of mutational frequency per variant sequence in North America from 2020 to 2024. The red points in the plot represent outliers calculated based on quartiles. The median values are marked to the right of the green boxes, and the blue smoothed line represents the connected mean values across each time period, obtained through cubic spline interpolation; (B) Temporal trends in virus lineage counts across six continents from 2020 to 2024. This chart depicts the trends in the number of virus lineages observed on each of six continents over a five-year period, highlighting considerable fluctuations and a pronounced peak observed in the North America region. The variations and peak may suggest differences in viral evolution or the effectiveness of regional response strategies.

(p < 0.001, KS test). For example, North American Fitness increased from 0.227 in early 2020 to 0.930 in 2024 (Table 2), accompanied by a substantial sample size advantage (accounting for 95.46% of cases), indicating a strong evolutionary trend. Europe exhibited similarly significant differences, likely reflecting the impact of high vaccination rates and population density in accelerating variant evolution. In contrast, Africa and Oceania, with smaller sample sizes, showed smaller but still significant differences between real and random sequence distributions (p < 0.001, KS test), suggesting weaker yet still detectable selective pressures in these regions. South America and Asia displayed intermediate trends, correlated with regional public health measures and data coverage. In summary, comparison with the null model demonstrates that the increases in Fitness and IEI of SARS-CoV-2 S protein sequences

be driven by selective pressures, such as immune responses triggered by vaccination, natural infection, or environmental factors. Outlier analysis further supports this conclusion: real sequences exhibited extreme Fitness and IEI values (e.g., Fitness > 0.9, IEI > 0.6), which markedly exceed the typical range of random sequences. For instance, the highest Fitness value recorded in North America from April to May 2024 (0.940, Table 2) and the maximum IEI value (0.563) were far above the random sequence averages (0.2046 and 0.1895), reflecting selection for enhanced transmissibility and immune escape. Across continents, trends in North America and Europe, where sequencing data are abundant, showed particularly pronounced differences between the Fitness and IEI distributions of real sequences and their corresponding random sequence distributions

Overall, the above results highlight the evolutionary trends in the Fitness of S protein variants in all the six continents, demonstrating an increase in Fitness over time.

are the result of selective evolution rather than random effects from neutral mutations. The distribution of real sequences significantly deviates from the null model expectations, particularly in data-rich regions such as globally and North America, indicating that selective pressures (e.g., immune pressure and environmental factors) have shaped the virus’s evolutionary trajectory. This also underscores the statistical robustness of the fitness and immune escape predictions presented in this study.

3.2.6 Temporal evolution of immune escape capacity in SARS-CoV-2 S protein variants The smoothed mean IEI showed a general increasing trend over time, indicating that the immune escape capability of S protein variants has progressively improved (Figure 5A). Early time periods exhibited lower IEI values with significant variability and numerous outliers, suggesting diverse immune escape capabilities among early variants. As time progressed, the IEI values increased, with the variability and number of outliers decreasing, reflecting more consistent and higher immune escape capabilities among newer variants. In the IEI curves, the trajectories for all six continents generally exhibited an upward trend, yet each showed one or more periods of decline or stagnation over shorter intervals. For instance, the IEI for North America reached a local trough in 2021 (Figure 5A). Figure 5B highlights the evolutionary trends in the immune escape capabilities of S protein variants across the six continents, showing an increase in IEI over time with reduced variability among more recent variants. However, in 2021, the IEI for the other five continents also exhibited short-term declines, similar to the results observed in North America (Figure 5B, Supplementary Figures S11–S15).

3.2.5 Temporal fitness evolution of SARS-CoV-2 S protein variants Temporal Fitness over the four-and-a-half-year period from January 2020 to May 2024 can be roughly divided into three stages: The First stage (Jan 2020 - Mar 2022), the second stage (Mar 2022 Mar 2023), and the third stage (Mar 2023 - May 2024) (Figure 4A). We found an increasing trend in the Fitness values of S protein variants over time. The virus with the lowest Fitness was from China (ancestral type, QZA85478.1, collect date 2020-02-23), with a fitness value of 0.234 (the lowest globally). Therefore, the Fitness values of all samples were compared to the wild type from China. In the early stage of the outbreak, the rate of change in Fitness (the slope of the curve) was not high, and the Fitness values were not high. In the middle stage, the rate of change in fitness sharply increased, which correlates with enhancement of the virus’s immune escape capability (Figure 5A). In the late stage, the growth rates of Fitness values and immune escape levels both slowed down, but their values had reached very high levels. In the first stage, there were many outliers with Fitness values higher than the maximum value of the boxplot, which is a significant characteristic of the early outbreak of SARS-CoV-2. The numerous outliers indicated that the virus evolved rapidly during the early stage of the outbreak, with a large accumulation of mutations. The more mutations there were, the higher the Fitness of the S protein, resulting in many variants with Fitness values significantly exceeding the mean Fitness during this phase (Figure 4A). In the second stage, there was a notable decrease in the number of outliers exceeding the boxplot’s maximum value, while a substantial proportion of outliers fell below the minimum value. Throughout this stage, not only did these low-Fitness variants continue to circulate, but high-Fitness variants also emerged more frequently. The Fitness levels increased at the fastest rate during this phase, as evidenced by the steep slope of the smoothed mean Fitness curve (Figure 4A). In the third stage, the prevalence of low-Fitness variants was very rare, and there were also fewer variants with Fitness values above the average, suggesting that this is a major characteristic of the end of the pandemic. During this stage, although the Fitness values were high, the slope of the smoothed Fitness curve decreased significantly. At the same time, there were very few variants with Fitness values above the mean, indicating that the rate of virus evolution had slowed down (Figure 4A). Similar characteristics were also observed in the results of the other five continents (Figure 4B, Supplementary Figures S6–S10).

3.2.7 Sensitivity analysis of outlier impact For the two outliers in North America (WZD59850.1 and WIJ15993.1, see Figures 4A, 5A), metadata verification indicated that their collection dates in early 2020 were inconsistent with their high mutation counts (66 and 42), possibly due to recording errors. After their removal, the molecular clock rate remained at 25.9223 substitutions per year (change <0.0001%), and the mean Fitness and IEI values in North America showed no significant changes (both <0.001%). Thus, the impact of these two outliers was significantly diluted and did not alter the main conclusions.

4 Discussion This retrospective study elucidates the dynamic evolution of the SARS-CoV-2 spike protein from January 2020 to May 2024, revealing significant shifts in viral adaptability and immune escape capabilities. Utilizing advanced protein language models, our research emphasizes the role of genetic mutations in shaping the trajectory of the COVID19 pandemic, revealing intricate mechanisms by which the virus adapts to the human immune system. In this study, we constructed a null model based on data from six continents and the overall dataset, providing a baseline for evaluating the fitness and immune escape trends of SARS-CoV-2 S protein variants. Significant deviations of the adaptability and immune escape index (IEI) of real sequences from the expectations of the null model (see Section 3.3) suggest that adaptive evolution plays a critical role in enhancing viral

Temporal analysis of Fitness levels for S protein variants. (A) Fitness trends in North America: The red points in the plot represent outliers calculated based on quartiles. The median values are marked to the right of the green boxes, and the blue smoothed line represents the connected mean values across each time period, obtained through cubic spline interpolation. The n value marked in black in the figure indicates the sample size of variants in a certain time period; (B) Longitudinal comparison of fitness trends across six continents: This graph displays the smoothed mean Fitness values over time, highlighting significant regional variations and trends in the evolutionary adaptation of S protein variants. Each line represents a different continent, illustrating comparative rises in fitness levels, which may suggest differences in variant adaptability and potential immune escape efficiency.

those exerted by high population densities accelerating virus mutation and transmission, while extensive public health interventions could limit the spread of these variants (45, 46). Compared to the original samples discovered in Wuhan, the top 20 SARS-CoV-2 variants in North America have shown higher adaptability and immune evasion capabilities, suggesting that the virus has reached a high level of adaptation in human hosts. However, the pace of the virus’s evolution has slowed, likely because it has found a relatively stable state of adaptation within the current biological and social environments. Nevertheless, whether it will gradually evolve into a seasonal virus, much like seasonal influenza requires ongoing observation of the virus’s longterm behavioral patterns and its impact on public health. Thus, claiming that the virus will evolve into a seasonal flu remains

transmissibility and immune escape capabilities. We incorporated an amino acid substitution rate (25.9223 substitutions per year) into the null model design and employed a uniform random mutation generation approach, further confirming that the observed evolutionary trends are not merely a simple product of neutral drift. The sequence variation model proposed by Lee et al., based on the frequency distribution of actual variants, could be integrated in the future to optimize the null model, better capturing mutation hotspots and variant competition effects, thus deepening the understanding of viral evolution mechanisms (44). Geographic and temporal variations indicate that the virus’s adaptability and immune escape indices vary with environmental conditions and the genetic diversity of host populations. These variations might reflect different evolutionary pressures, such as

Temporal analysis of IEI for S protein variants. (A) IEI trends in North America: This boxplot graphically represents the distribution and temporal progression of the IEI for S protein variants in North America over a five-year period. The blue line traces the smoothed mean value of the IEI, illustrating an overall trend of increasing immune escape capabilities over time. The graph highlights the variability of the index, with some periods showing a high density of outlier values, suggesting episodes of significant evolutionary changes in the virus’s immune escape mechanisms. Each plotted point represents an individual variant’s measured IEI, providing a comprehensive overview of the changing landscape of viral resistance against immune responses over the specified timeframe; (B) Comparative analysis of IEI across six continents: This graph displays the smoothed mean values of the IEI for S protein variants across five continents, charting the trends from 2020 to 2024. Each colored line represents the trajectory of immune escape capabilities in South America, Oceania, North America, Europe, Asia, and Africa, indicating how these capabilities have evolved over the years. The chart highlights regional differences in the evolution of the virus’s immune escape mechanisms, with some continents showing more pronounced rises in immune escape indices than others. This visualization aids in understanding the geographical variation in viral adaptation and the potential implications for global public health strategies.

variants with higher immune escape capabilities may have been effectively suppressed for a period of time, resulting in a temporary decrease in the overall IEI (50). However, despite the significant increase in global vaccination rates over time, the IEI of the virus has not shown a sustained downward or stagnant trend. This indicates that the continuous accumulation of mutations in the S protein has enhanced the virus’s adaptability, leading to a persistent rise in immune escape capabilities. The rapid evolution of the virus means that newly developed vaccines quickly become less effective, thereby contributing to the ongoing increase in the IEI (21).

premature and requires further scientific evidence to support such a prediction. We observed that the IEI for North America reached a local trough in 2021. This could be attributed to several factors. Firstly, starting in 2021, various public health interventions were implemented by countries and health organizations, such as lockdowns and travel restrictions (47, 48). These measures likely curtailed the spread of the virus, particularly variants with high immune escape capabilities (49) to accumulate new mutations to evade immune. Secondly, with the widespread rollout of vaccines, Frontiers in Immunology

Additionally, our findings during the study period (from Apr 1, 2024 to May 15, 2024) indicated a higher adaptability of spike protein variants in North America as of early 2024, suggesting that the virus in this region may be evolving towards a more stable phase of adaptability. This stabilization might signal the virus transitioning towards an endemic phase, potentially manifesting a periodic outbreak pattern similar to seasonal influenza (46, 51, 52). Although this study is primarily based on North American data, we believe its conclusions have global applicability. The high sequencing coverage in North America makes it a robust foundation for observing the evolutionary dynamics of SARSCoV-2, such as the increased Fitness of the JN.1 lineage. The World Health Organization (WHO, 2024) reported that, as of April 2024, more than 94% of global SARS-CoV-2 sequences were derived from JN.1 (see https://www.who.int/news/item/2604-2024-statement-on-the-antigen-composition-of-covid-19vaccines), and this trend was further confirmed in December 2024, when all circulating variants were descendants of JN.1 (see https:// www.who.int/news/item/23-12-2024-statement-on-the-antigencomposition-of-covid-19-vaccines). This global consistency, alongside earlier observations of mutations like D614G and N439K spreading across multiple regions (2), indicates that the evolutionary trends observed in North America have been validated in other regions. Furthermore, the universality of immune selection pressure, such as the immune escape properties of JN.1, aligns with findings that immune-driven evolution is a global phenomenon (2), further supporting the global relevance of our conclusions (see https://www.who.int/news/item/23-12-2024-statement-on-theantigen-composition-of-covid-19-vaccines). Notably, despite increasing global vaccination coverage, the virus’s IEI continues to rise (49). This highlights the high adaptability of SARS-CoV-2 under immune pressure and its capacity to accumulate new mutations to evade immune responses (45). Therefore, ongoing genetic surveillance and timely adjustments in vaccine strategies are crucial to manage potential outbreaks. This study employed a protein language model to conduct a retrospective analysis of the spike protein of the SARS-CoV-2 virus. Methodologically, CoVFit utilized historical data to develop a deep learning model, on which basis our study predicted the protein fitness and immune evasion capabilities of historical spike protein (S protein) sequences. To address potential inquiries, we clarify that the training data for the CoVFit model comprised 21,751 genotypefitness data points, covering 12,914 genotypes across 17 countries (19). Due to the presence of different mutations or variant combinations that can constitute distinct genotypes, many of the genotypes contain repeated mutations. Thus, the number of variants used in training the CoVFit model is estimated to be in the hundreds to thousands, which can be precisely quantified using CoVFit’s original dataset. Additionally, in our study, the total number of global variants analyzed was 160,892, and the variant amino acid sequences used did not include any uncertain ‘X’ entries. Consequently, in this retrospective analysis, only about 2% of the data overlaps with the model training data. To ensure the integrity

of the sample, we did not exclude this very small proportion of overlapping data. Therefore, although the retrospective study may include a minimal portion of the data used during model training, this does not affect the primary conclusions drawn from our research. There are two data points from North America that are exceptionally high in terms of the number of mutations, Fitness values, and IEI values. The Fitness/IEI/Mutation values are 0.944/ 0.571/66 (WZD59850.1, JN.1) and 0.712/0.404/42 (WIJ15993.1, BA.4.6), with collection dates of 2020-01–20 and 2020-02–02 respectively. Firstly, we speculate that the collection dates of these two samples may have been recorded incorrectly. This is because other samples with a Fitness value greater than 0.9 occurred after April 2023, and the remaining samples with Fitness values above 0.7 appeared after October 2021. In the case of WZD59850.1, if the recorded collection date is correct, this would imply that the sample underwent an astounding number of 66 mutations in an incredibly short period during the early stages of the virus outbreak. The source of this sample may not be Wuhan, China, and it could represent mutations accumulated locally in the USA over 2–3 years, though further phylogenetic analysis is needed to confirm this hypothesis.

5 Limitations of this study Despite providing comprehensive analysis, this study has several limitations that need to be considered. First, the accuracy of our predictions largely depends on the quality of the data used, and our dataset, comprising 2.5 million sequences (approximately 160,892 variants), may still exhibit biases due to North America’s overrepresentation. This could potentially skew the understanding of global viral evolution patterns. For instance, although we addressed two North American outliers (WZD59850.1 and WIJ15993.1, see Sections 2.7 and 3.2.7) through sensitivity analysis, confirming their negligible impact on the results (molecular clock rate variation <0.001%, Fitness and IEI mean variation <0.01%), the extremely limited sample sizes from nonNorth American regions (e.g., Africa, Oceania, and South America), such as fewer than 300 variants in Africa (see Section 2.4), may result in insufficient detection of region-specific evolutionary trends. Second, although the CoVFit protein language model represents significant progress in predicting fitness and immune escape capabilities, it is fundamentally limited by the quality and diversity of its training data. The model was fine-tuned on 21,751 genotype-fitness data points from 17 countries (Section 2.4), but changes in viral properties not adequately captured in these training sequences—such as complex mutation interactions (epistasis) or rare variant effects—might not be accurately reflected in the model’s predictions. Additionally, while CoVFit was pre-trained on 1,506 types of coronaviruses, its ability to fully capture SARS-CoV-2specific evolutionary pressures may still be constrained by the representativeness of the training dataset.

Lastly, while we strive for precision in our analyses, computational predictions of immune escape capabilities cannot fully substitute for empirical validation in a laboratory setting. Continuous verification of computational results with experimental data is necessary to ensure the accuracy and relevance of the predictions made. These limitations underscore the importance of ongoing research, continuous data collection, and model updates. In the future, the predictive accuracy and utility of computational tools in virology can be enhanced by increasing sequence data from nonNorth American regions, improving the model’s ability to capture mutation interactions, and integrating in vitro experimental validation to complement computational predictions. Specifically, future studies could employ pseudovirus neutralization assays to experimentally validate the predicted fitness and immune escape capabilities of SARS-CoV-2 variants, providing a more robust assessment of the model’s predictions.

Author contributions SP: Conceptualization, Investigation, Writing – original draft. LL: Writing – original draft, Investigation, Methodology. LC: Writing – original draft, Writing – review & editing, Resources. SS: Writing – original draft, Writing – review & editing, Resources. MM: Writing – original draft, Writing – review & editing, Resources. MB: Writing – original draft, Writing – review & editing, Resources. JB: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.

📖 中文全文 Chinese Full Text

中文

# 翻译

**类型** 原创研究 **发表日期** 2025年6月18日 **DOI** 10.3389/fimmu.2025.1576414 **开放获取** **编辑** Maolin Lu, 德克萨斯大学泰勒健康科学中心,美国 **审稿人**

Arvind Ramanathan, 阿贡国家实验室(DOE),美国 Md. Aminul Islam, 杜兰大学,美国 *通讯作者*

Justin Bahl justin.bahl@uga.edu Sihua Peng Sihua.Peng@uga.edu **收稿日期** 2025年2月13日 **接受日期** 2025年5月30日

**演化适应性与免疫逃逸:基于蛋白质语言模型的SARS-CoV-2刺突蛋白回顾性分析(2020–2024)**

Sihua Peng 1,2*,Leke Lyu 1,3,Ludy Registre Carmola 2,Sachin Subedi 1,2,3,M. H. M. Mubassir 1,2,3,Mohamed A. Bakheet 1,2,Justin Bahl 1,2,3,4*

1 佐治亚大学传染病生态学中心,美国佐治亚州雅典市 2 佐治亚大学传染病学系,美国佐治亚州雅典市 3 佐治亚大学生物信息学研究所,美国佐治亚州雅典市 4 佐治亚大学流行病学与生物统计学系,美国佐治亚州雅典市

Peng S, Lyu L, Carmola LR, Subedi S, Mubassir MHM, Bakheet MA, Bahl J(2025)演化适应性与免疫逃逸:基于蛋白质语言模型的SARS-CoV-2刺突蛋白回顾性分析(2020–2024). *Front. Immunol.* 16:1576414. doi: 10.3389/fimmu.2025.1576414

**版权**

© 2025 Peng, Lyu, Carmola, Subedi, Mubassir, Bakheet及Bahl. 本文为开放获取文章,依据知识共享署名许可协议(CC BY)条款分发。在其他论坛使用、分发或转载时,须注明原作者和版权所有人,并按照公认的学术规范引用本期刊的原始出版物。任何不符合上述条件的使用、分发或转载均不被允许。

**引言:** COVID-19大流行给全球健康带来了严峻挑战。理解SARS-CoV-2的演化动力学,尤其是适应性与免疫逃逸,对公共卫生至关重要。本研究利用蛋白质语言模型评估遗传变异如何影响病毒的适应性和免疫逃逸能力。

**方法:** 我们应用CoVFit模型预测适应性与免疫逃逸指数(IEI),并基于中性演化零模型进行验证。我们分析了2,504,278条SARS-CoV-2刺突蛋白序列,包含160,892个变异株,追踪了2020年至2024年5月的演化过程,比较了真实突变体与随机突变体的适应性和IEI。

**结果:** 分析显示,北美样本的适应性(均值从2020年的0.227上升至2024年的0.930)和IEI(均值从0.171上升至0.555)均呈上升趋势。在全球范围内,真实突变体与随机突变体(由零模型生成)的适应性和IEI比较揭示了统计学上的显著差异(真实突变体适应性0.3849 vs. 随机突变体0.2046,p < 0.001,KS检验;真实突变体IEI 0.2894 vs. 随机突变体0.1895,p < 0.001,KS检验),表明存在强烈的选择压力;JN.1谱系占据主导地位(截至2022年4月占序列的94%),凸显了其演化优势。

**结论:** CoVFit为理解SARS-CoV-2演化提供了关键见解,有助于疫苗设计。尽管采取了干预措施,病毒仍在持续适应,这凸显了利用CoVFit等工具进行监测和采取适应性策略以做好准备的必要性。

SARS-CoV-2,刺突蛋白,蛋白质语言模型,蛋白质适应性,免疫逃逸,回顾性分析 *免疫学前沿* 01 frontiersin.org Peng et al. 10.3389/fimmu.2025.1576414

既往研究主要关注特定变异株或短期趋势,且常依赖于忽略突变间相互作用的统计模型(27–29),未能提供大流行期间S蛋白动态的全局分析。

此前的研究,如Islam等(30)关于XBB.1.5免疫逃逸的研究以及Hasan等(31)关于疫苗效力与气象因素的研究,均对SARS-CoV-2演化进行了探索。然而,这些工作主要聚焦于特定变异株或短期区域趋势,未涉及2020年至2024年S蛋白的长期全球动态。本研究利用CoVFit模型,基于2024年1月1日至2024年5月15日收集的S蛋白序列,回顾性评估了2020年至2024年S蛋白的适应性与免疫逃逸趋势。本研究旨在阐明突变如何随时间和区域塑造病毒特征。该系统性分析弥补了先前研究的不足,为预测未来变异株和优化公共卫生策略提供了新的科学见解。

**1 引言**

由SARS-CoV-2引起的COVID-19大流行带来了前所未有的全球性挑战(1)。SARS-CoV-2为正义单链RNA病毒,其高突变率导致了大量变异株的出现,显著增强了其传播能力和免疫逃逸能力(2–4)。尽管疫苗接种降低了重症率,病毒的持续演化仍不断挑战着疫苗策略(5, 6)。SARS-CoV-2刺突(S)蛋白是决定其感染人类宿主能力的关键因子,通过与ACE2受体结合介导病毒进入细胞(7),并且由于其介导病毒进入和诱导中和抗体应答的关键作用,成为大多数疫苗的主要靶点(8–10)。病毒的演化轨迹深受免疫逃逸、环境压力和遗传改变等因素的影响(2–5)。因此,追踪S蛋白的适应性和免疫逃逸趋势对于开发新型疫苗和治疗策略至关重要。然而,传统分析方法难以全面捕捉其长期动态,需要借助先进的计算工具来阐明病毒演化的模式。

蛋白质语言模型(PLMs)通过将氨基酸序列类比为句子,利用大规模序列数据捕捉蛋白质的生化特性,为研究病毒演化提供了新的视角(11)。Transformer架构的出现标志着预测能力的重大进步(12)。例如,Rao等人率先将BERT应用于蛋白质预测,开发了TAPE模型(13);Elnaggar等人通过ProtTrans扩展了其在不同蛋白质家族中的应用(14);Rivers等人利用在UniProt数据库上训练的ESM-1b提升了下游任务的性能(15)。在这些进展的基础上,Lin等人开发了具有15亿参数的ESM-2模型,能够直接推断蛋白质结构(16);Ito等人则利用基因型-适应性数据和高通量深度突变扫描(DMS)实验数据对ESM-2进行微调(17, 18),创建了CoVFit模型,绘制了SARS-CoV-2的适应性图谱(19)。DMS将深度测序与系统突变分析相结合,为评估S蛋白的免疫逃逸潜力提供了有力支撑(20, 21)。

近年来,PLMs在SARS-CoV-2演化研究中日益受到重视。Ma等人构建了一个结合规律性和随机性的深度学习模型来预测病毒演化,验证了几种高传播力变异株,但其5,000轮训练可能存在过拟合风险(22)。Lamb等人利用ESM-2在6,500万条蛋白质序列上训练模型以揭示演化潜力,但缺乏特定领域的微调(23)。King等人开发了VPRE模型,利用有限数据预测未来变异株,但其依赖20,000条合成序列可能引入人为特征(24)。Elkin等人提出了DNMS方法预测S蛋白新突变,但仅限于单氨基酸替换(25)。Zvyagin等人采用GenSLM模型模拟病毒动态,但受限于较小的训练数据集(26)。尽管这些研究展示了PLMs的潜力,*免疫学前沿*

**2 材料与方法**

本研究的技术路线如图1所示,数据来源于2020年1月至2024年5月期间收集的全球SARS-CoV-2 S蛋白序列。

**2.1 数据收集**

从NCBI SARS-CoV-2数据枢纽下载了2020年1月1日至2024年5月15日期间收集的共计2,504,278条SARS-CoV-2 S蛋白序列。将序列按三个月间隔分为18个时间段,以分析SARS-CoV-2适应性和免疫逃逸的演化轨迹(https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&VirusLineage_ss=taxid:2697049)。包含超过五个未鉴定字符的序列被排除在分析之外。

**2.2 变异序列鉴定与突变计数**

在SARS-CoV-2流行病学中,"突变"、"变异株"和"毒株"常被互换使用,但它们具有不同的科学含义。蛋白质突变是指蛋白质序列的实际变化,如D614G,即刺突蛋白第614位天冬氨酸被甘氨酸取代(32)。序列不同的基因组通常被称为变异株。这一术语可能较为模糊,因为两个变异株之间可能相差一个或多个突变。当变异株表现出显著不同的表型特征(如抗原性、传播力或毒力的差异)时,则被视为毒株(33, 34)。在本研究中,我们将"变异株"定义为相差一个或多个突变的刺突蛋白S氨基酸序列。这些变异株中部分可能未表现出抗原性、传播力或毒力的差异,但本文中提及的任何两个变异株在氨基酸序列上均有所不同,通常称为变异序列或简称为变异株。

各时间段下载的S蛋白数据包含大量重复序列。去除18个时间段内各自的重复序列后,获得各时间段内唯一的氨基酸序列,以下称为"变异株"。共获得160,892个变异株(附表S1)。然而,部分样本在不同时间段间可能存在重复。

每个变异株的突变位置和频率各不相同。为研究突变频率随时间的变化,我们计算了各变异序列中突变的频率。使用三次样条插值连接各时间段突变计数的均值。用于去除重复序列、计算突变出现频率和发生次数的代码可在https://github.com/pengsihua2023/SARS-CoV-2-Fitness-IEI获取。

**2.3 系统发育与分子钟分析**

我们收集了2020年至2024年间采样的全球S蛋白序列。选取了5,000条具有详细采样日期的随机子集。使用MAFFT V 7.520(35)将序列与武汉-Hu-1参考基因组进行比对。使用IQ-TREE V 2.2.2.6(36)推断系统发育树,采用LG+I+G替代模型,应用-czb标志将短分支折叠为多分支。使用R中的ape包(37)计算树根与所有末端之间的遗传距离。将遗传距离对采样日期作图以估算分子钟速率。

图1

利用CoVFit对SARS-CoV-2刺突蛋白适应性与免疫逃逸进行回顾性分析(2020–2024)的技术路线。该图展示了使用CoVFit模型分析SARS-CoV-2刺突(S)蛋白变异株的适应性和免疫逃逸指数(IEI)的工作流程。该流程首先使用多种冠状病毒数据对预训练的ESM-2模型进行领域自适应微调,随后使用SARS-CoV-2数据进行第二步微调,最终预测历史SARS-CoV-2数据的适应性和IEI。各组成部分如下:(A)蛋白质序列数据——来自真核生物、细菌、古菌和病毒的序列,用于预训练ESM-2(650M)模型;(B)ESM-2——用于学习通用蛋白质表示的预训练蛋白质语言模型;(C)S蛋白变异株——2020年1月至2024年5月收集的SARS-CoV-2刺突蛋白序列;(D)适应性预测——S蛋白变异株的适应性预测;(E)蛋白质序列数据(冠状病毒)——来自不同冠状病毒物种的序列,用于ESM-2的领域自适应微调;(F)ESM-2(冠状病毒微调)——在冠状病毒序列上微调的ESM-2模型,用于SARS-CoV-2特异性任务;(G)CoVFit——支持多种任务的微调模型,包括适应性和免疫逃逸预测;(H)免疫逃逸指数预测——基于与1,548种单克隆抗体(mAbs)的相对结合亲和力预测免疫逃逸能力。

零模型旨在评估观察结果是否显著偏离中性演化预期,从而验证计算结果的可靠性。零模型基于七个数据集设计,涵盖六大洲(非洲、亚洲、欧洲、北美洲、大洋洲和南美洲)以及一个综合数据集(合并所有六大洲数据)。

获得了21,751个基因型-适应性数据点,覆盖17个国家的12,914种基因型,表明S蛋白的适应性最初来源于公开数据集(38, 39)。最后,将获得的适应性数据缩放至0–1范围,以便于模型训练(38, 39)。

本研究采用CoVFit蛋白质模型分析适应性和免疫逃逸指数(IEI)的时间趋势以及SARS-CoV-2变异株在不同大洲的地理分布。模型文件从Zenodo下载(https://zenodo.org/records/10911205)。我们使用Clustal Omega 1.2.3(40)对氨基酸序列进行多序列比对,并将比对后的S蛋白序列输入CoVFit模型以预测S蛋白的适应性值。北美适应性值取美国和加拿大的平均值。欧洲取德国、英国、瑞士、瑞典、西班牙、荷兰、意大利、法国、丹麦和比利时的平均值。亚洲取韩国、日本和印度的平均值。澳大利亚的适应性值视为大洋洲的平均值,巴西的适应性值视为南美洲的平均值。由于非洲的基因型数量未超过300,CoVFit模型在训练期间未包含非洲国家数据。因此,非洲没有适应性预测值。为完整性起见,将17个国家的平均适应性预测值作为非洲的适应性平均值。因此,在使用CoVFit进行模型预测时,输入非洲的S蛋白序列数据,将17个国家的平均适应性值作为非洲的适应性平均值。

还计算了北美近期流行变异株的适应性值。使用了2024年4月1日至2024年5月15日期间收集的2,170条S蛋白氨基酸序列(含543个变异株)进行分析。

**2.6.1 中性演化下的随机序列生成**

零模型模拟S蛋白在中性演化条件下的演化(不受宿主免疫系统、疫苗接种或环境因素影响),反映随机突变的积累。这为验证真实序列和随机突变序列的适应性/IEI提供了统计基线。以武汉-Hu-1序列(GenBank: MN908947.3,1,273个氨基酸)为模板,基于图2B中的氨基酸替换率(25.9223次替换/年),通过在各位点均匀随机突变来模拟4.375年(2020年1月至2024年5月)的中性漂变。

**2.6.2 演化参数校准**

为反映真实的演化动力学,通过以下步骤确定关键参数:

时间跨度:模拟持续时间设为4.375年,对应本研究的时间窗口;

突变率计算:根据观测数据,S蛋白在4.375年内平均累积25.9223个氨基酸突变,据此计算每位点年突变率:

m = Nmut / L = 25.9223 / 1273 = 0.02036 突变/位点/年

其中Nmut为每年突变总数,L为序列长度。

通过文献回顾,我们发现S蛋白中中性突变的比例:总体约为10–30%,受体结合域(RBD)<10%,非RBD区域为20–40%(2, 20, 27, 41, 42)。

中性比例:设定20%的突变由中性演化驱动,将有效突变率调整为m_neutral = m × 0.2;

分支长度:理论分支长度计算为m_neutral × T,结果为0.0178。

**2.5 免疫逃逸指数**

CoVFit模型可预测不同单克隆抗体(mAbs)的相对结合亲和力。通过输入SARS-CoV-2 S蛋白序列,模型可预测1,548种mAbs的相对结合亲和力。我们对这些预测亲和力值取平均,将平均值称为IEI,用于描述变异株的免疫逃逸能力。IEI越高,变异株的免疫逃逸能力越强。按照前述方法对全球和北美数据集计算了IEI。

**2.6.3 演化模型配置**

替代模型:WAG氨基酸替代矩阵(Whelan-And-Goldman模型);

系统发育树:构建最简系统发育树;

中性约束:设定dN/dS = 1,仅保留中性突变。

**2.6 构建零模型用于适应性和免疫逃逸的基准比较**

**2.6.4 变异株生成**

为验证SARS-CoV-2 S蛋白序列的适应性和免疫逃逸指数(IEI)预测的统计稳健性,我们开发了一个零模型,生成随机序列作为中性演化基线。通过比较随机数据与真实数据,

进行N次独立演化模拟(如2,604次,对应南美洲的典型采样规模),每次模拟通过以下步骤生成变异株:

- 使用Pyvolve(43)中的Evolver模块沿指定系统发育树演化序列; - 通过泊松过程随机引入符合中性约束的突变; - 记录最终突变序列并以FASTA格式保存。

生成随机突变序列的代码可在以下地址获取: https://github.com/pengsihua2023/SARS-CoV-2-Fitness-IEI/tree/main/code

**2.6.5 Kolmogorov-Smirnov检验评估真实变异株对中性演化的偏离**

我们使用CoVFit模型预测随机生成变异株的适应性和免疫逃逸指数(IEI)值,建立中性演化下的预期分布。随后,应用Kolmogorov-Smirnov(KS)检验(p < 0.05)比较真实SARS-CoV-2刺突蛋白变异株与随机变异株的分布,评估观察到的演化模式是否显著偏离中性预期。

**2.8 北美近期流行变异株S蛋白适应性与免疫逃逸的预测研究**

从2024年4月1日至2024年5月15日下载了美国2,170条S蛋白氨基酸序列(含543个变异株)。随后对所有变异株S蛋白的适应性和免疫逃逸能力进行了预测研究。需注意,下载的美国样本实际上代表了整个北美地区的样本量。

**2.9 全球S蛋白适应性与免疫逃逸的回顾性分析**

将时间段按三个月间隔划分,下载了2020年1月1日至2024年5月15日六大洲的S蛋白数据,去除同一时间段内的重复序列。随后对各时间段和各大陆S蛋白的适应性和免疫逃逸能力进行了回顾性研究。

**2.7 异常元数据验证与敏感性分析**

为验证北美两个极端异常值(WZD59850.1和WIJ15993.1)的元数据,我们通过NCBI SARS-CoV-2数据枢纽检查了它们的采集日期。WZD59850.1(报告日期2020-01-20,66个突变)和WIJ15993.1(报告日期2020-02-02,42个突变)与同期典型突变计数(通常<10个(5))不一致,提示可能存在日期错误。为评估其影响,我们剔除了这两个样本(占北美140,000个变异株的0.0014%),重新计算了分子钟速率以及北美的平均适应性和IEI值。

*免疫学前沿* 05 frontiersin.org Peng et al. 10.3389/fimmu.2025.1576414(附表S2)。我们发现JN.1谱系的变异株数量最多(n=1,082),而JN.1.7.2最少,仅有10个变异株。在某些谱系中,不同变异株的适应性和IEI存在明显差异。例如,JN.1.16的最高适应性为0.914,最低为0.863(附表S2)。

总之,我们确定了北美最值得关注的20个变异株,其中XAN64366.1(JN.1.16谱系)因其高适应性(0.925)和高IEI(0.585)值而最为显著。

**3 结果**

**3.1 美国预测研究:2024年1月1日至2024年5月15日**

使用CoVFit模型预测了美国543个变异株的适应性和IEI值,表1列出了适应性值最高的20个变异株。适应性值越高,变异株的传播潜力越大。适应性值最高的病例来自艾奥瓦州。这20个变异株之间的适应性值差异较小,范围为0.921至0.925,IEI差异也较小,范围为0.581至0.589。这20个变异株包含11个SARS-CoV-2谱系。例如,JN.1.16、JN.1.11.1和JN.1.7谱系各有三个变异株进入前20名(表1),表明不同数量的突变可导致不同的适应性值。这可能是因为不同的氨基酸突变可能显著改变蛋白质构象,影响S蛋白与人类ACE2受体的结合亲和力。

随后我们对这11个谱系进行了历史考察,鉴定了2020年至2024年间所有全球S蛋白变异株

**3.2 回顾性研究:2020年1月1日至2024年5月15日**

我们分析了变异株内的谱系和突变分布,鉴定了优势谱系、每个变异株的平均突变数、适应性和IEI的最大值与最小值,以及各特定时间段内该谱系在所有谱系中的占比。在六大洲中,北美占病例数的95.46%和变异株的89.66%。因此,此处主要展示北美的分析结果(表2)。其他五大洲的结果见补充材料(附表S3–S7)。

**表1** 美国SARS-CoV-2变异株适应性与IEI预测前20名

| 变异株登录号 | 谱系 | 采集日期 | 适应性 | IEI | |---|---|---|---|---| | XAN64366.1 | JN.1.16 | 2024-04-29 | 0.925 | 0.585 | | XBA97060.1 | JN.1.11.1 | 2024-05-09 | 0.924 | 0.584 | | XAW33708.1 | JN.1.16 | 2024-05-06 | 0.924 | 0.584 | | XAU78949.1 | JN.1.11.1 | 2024-04-20 | 0.924 | 0.584 | | XAU78842.1 | JN.1.7 | 2024-04-17 | 0.923 | 0.584 | | XAJ36120.1 | JN.1.11.1 | 2024-04-21 | 0.923 | 0.584 | | XAW33862.1 | JN.1.4.2 | 2024-04-29 | 0.923 | 0.586 | | XAJ04662.1 | JN.1.9 | 2024-04-10 | 0.923 | 0.585 | | XAN64414.1 | JN.1 | 2024-04-25 | 0.922 | 0.589 | | XAW33674.1 | BA.2.86.1 | 2024-05-04 | 0.922 | 0.589 | | XAO61989.1 | JN.1 | 2024-04-02 | 0.922 | 0.581 | | XAJ04710.1 | XDD | 2024-04-14 | 0.922 | 0.588 | | XAU78878.1 | JN.1.9 | 2024-04-24 | 0.921 | 0.588 | | WZH70794.1 | JN.1.16 | 2024-04-08 | 0.921 | 0.581 | | XBA97012.1 | JN.1.7.2 | 2024-04-30 | 0.921 | 0.588 | | XAW19132.1 | JN.1.8.1 | 2024-04-17 | 0.921 | 0.588 | | XAJ29041.1 | JN.1.7 | 2024-04-16 | 0.921 | 0.588 | | XAU78770.1 | JN.1.7 | 2024-04-05 | 0.921 | 0.588 | | XAU78782.1 | JN.1.4 | 2024-04-03 | 0.921 | 0.588 | | XAU78794.1 | JN.1.4 | 2024-04-03 | 0.921 | 0.588 |

*免疫学前沿* 采集日期 适应性 IEI

**3.2.1 S蛋白高演化率的揭示**

系统发育树(图2A)展示了不同的聚类和分支模式,可能对应不同的地理区域或时间聚类。这一全面的系统发育分析为理解SARS-CoV-2刺突蛋白的演化动力学提供了关键见解,增强了我们对其随时间传播和突变的认识。

图2B显示,分子钟估算揭示替换率约为每年25.9223次替换,表明2020年至2024年间全球采样的S蛋白序列具有较高的演化率。散点图(图2B)显示遗传距离随时间呈总体上升趋势,与估算的分子钟速率拟合良好(R² = 0.6789),表明在观察期间演化速率保持一致。

**3.2.2 S蛋白变异序列中突变的演化**

我们发现整个SARS-CoV-2大流行期间每个变异株突变数的分布可分为三个不同阶段(图3A,附图S1–S5)。

在北美,第一阶段大约从2020年1月至2022年12月,标志着病毒快速突变阶段。我们观察到大量异常值,代表具有极高突变数的序列。在大流行的中间阶段,即2022年1月至2023年3月,突变总数持续增加,但中位数以上的异常值数量减少,表明快速突变速率放缓。该阶段还记录了

**表2** 北美SARS-CoV-2变异株概况:谱系、突变、适应性和IEI

| 时间段 | 病例数/变异序列 | 优势谱系 | 优势占比 | 独特谱系数 | MMut | MaxFit | MFit | MaxIEI | MIEI | |---|---|---|---|---|---|---|---|---|---| | 2020年1–3月 | 10,055/400 | B.1 | 37.5% | 73 | 2 | 0.963 | 0.227 | 0.591 | 0.171 | | 2020年4–6月 | 19,662/968 | B.1 | 35.85% | 154 | 2 | 0.325 | 0.211 | 0.373 | 0.164 | | 2020年7–9月 | 18,434/1,159 | B.1 | 16.65% | 169 | 2 | 0.329 | 0.212 | 0.513 | 0.164 | | 2020年10–12月 | 45,478/3,264 | B.1.2 | 30.91% | 213 | 3 | 0.531 | 0.229 | 0.384 | 0.196 | | 2021年1–3月 | 140,838/10,916 | B.1.2 | 25.53% | 283 | 6 | 0.534 | 0.286 | 0.466 | 0.258 | | 2021年4–6月 | 177,356/11,233 | B.1.1.7 | 39.6% | 220 | 14 | 0.534 | 0.286 | 0.442 | 0.297 | | 2021年7–9月 | 382,456/21,392 | AY.44 | 11.53% | 203 | 20 | 0.645 | 0.363 | 0.372 | 0.254 | | 2021年10–12月 | 461,734/25,974 | AY.103 | 17.9% | 210 | 28 | 0.694 | 0.421 | 0.387 | 0.275 | | 2022年1–3月 | 247,674/9,632 | BA.1.1 | 39.11% | 185 | 49 | 0.773 | 0.527 | 0.436 | 0.313 | | 2022年4–6月 | 261,252/8,397 | BA.2.12.1 | 31.19% | 240 | 39 | 0.795 | 0.642 | 0.451 | 0.367 | | 2022年7–9月 | 253,298/11,225 | BA.5.2.1 | 12.71% | 390 | 40 | 0.806 | 0.715 | 0.459 | 0.398 | | 2022年10–12月 | 147,966/11,044 | BQ.1.1 | 8.82% | 626 | 42 | 0.837 | 0.755 | 0.476 | 0.424 | | 2023年1–3月 | 90,796/8,895 | XBB.1.5 | 23.66% | 706 | 53 | 0.891 | 0.780 | 0.518 | 0.441 | | 2023年4–6月 | 22,424/3,707 | XBB.1.5 | 27.65% | 562 | 50 | 0.901 | 0.808 | 0.532 | 0.459 | | 2023年7–9月 | 38,369/5,797 | FL.1.5.1 | 5.49% | 629 | 64 | 0.911 | 0.857 | 0.532 | 0.489 | | 2023年10–12月 | 44,399/6,486 | HV.1 | 14.75% | 534 | 63 | 0.924 | 0.895 | 0.551 | 0.522 | | 2024年1–3月 | 26,275/3,216 | JN.1 | 27.92% | 247 | 72 | 0.913 | 0.901 | 0.545 | 0.536 | | 2024年4–5月 | 2,170/543 | JN.1 | 15.65% | 46 | 68 | 0.940 | 0.930 | 0.563 | 0.555 |

MMut,平均突变数;MaxFit,最大适应性;MFit,平均适应性;MaxIEI,最大免疫逃逸指数;MIEI,平均免疫逃逸指数。

中位数以下的突变数量较多,表明突变较少的早期病例持续存在。在第三阶段,即2023年4月以后,突变较少和突变较多的异常值数量均显著减少,提示大流行可能正在消退(图3A)。其他五大洲也观察到类似模式(附图S1–S5)。

**3.2.3 不同时间段全球SARS-CoV-2谱系数量的演化**

为理解SARS-CoV-2刺突(S)蛋白序列的演化趋势,我们将真实序列的适应性和免疫逃逸指数(IEI)值与基于零模型生成的随机序列的值进行了比较(零模型生成方法见第2.6节)。零模型通过生成具有随机突变的序列来模拟中性演化,提供基线以评估观察到的趋势是由选择驱动还是可能随机产生。

在全球范围内,真实序列的适应性值分布(均值=0.3849)与随机序列(均值=0.2046)存在显著差异(p < 0.001,KS检验)(附表S8)。同样,真实序列的IEI值分布(均值=0.2894)与随机序列(均值=0.1895)也存在显著差异(p < 0.001,KS检验)(附表S9)。这些结果表明,全球观察到的适应性和IEI值显著高于中性演化预期,提示这些性状可能

在全球数据集中,共代表了2,442个谱系。在整个观察期间,北美的谱系数量持续高于其他大洲(图3B)。这种显著差异可能归因于北美测序的样本量更大,从而检测到更多的谱系。

具体而言,北美的谱系数量呈现三个明显峰值:第一个峰值出现在2021年底,达到显著高点;第二个峰值出现在2022年底,再次呈现显著增长;第三个峰值出现在2023年9月左右,标志着第三次大幅增长。

相比之下,其他大洲的谱系数量随时间保持相对稳定。例如:欧洲和亚洲在整个期间谱系数量相对稳定,仅有小幅波动,未出现与北美相当的显著峰值;非洲、大洋洲和南美洲呈现

(A)2020年至2024年北美各变异序列突变频率的时间分析。图中的红点代表基于四分位数计算的异常值。中位数标记在绿色箱体的右侧,蓝色平滑线表示通过三次样条插值获得的各时间段均值的连接线。(B)2020年至2024年六大洲病毒谱系数量的时间趋势。该图表描绘了五年期间六大洲各自观察到的病毒谱系数量趋势,突出了显著波动以及北美地区观察到的明显峰值。这些波动和峰值可能提示病毒演化的差异或区域应对策略的有效性。

(p < 0.001,KS检验)。例如,北美适应性从2020年初的0.227上升至2024年的0.930(表2),伴随大量样本优势(占病例数的95.46%),表明存在强烈的演化趋势。欧洲表现出类似的显著差异,可能反映了高疫苗接种率和人口密度对加速变异株演化的影响。相比之下,非洲和大洋洲样本量较小,真实序列与随机序列分布之间的差异较小但仍显著(p < 0.001,KS检验),提示这些区域的选择压力较弱但仍可检测到。南美洲和亚洲呈现中间趋势,与区域公共卫生措施和数据覆盖范围相关。

总之,与零模型的比较表明,SARS-CoV-2 S蛋白序列的适应性和IEI的增加

受疫苗接种、自然感染或环境因素等免疫反应所施加的选择压力所驱动。异常值分析进一步支持了这一结论:真实序列表现出极端的Fitness和IEI值(例如,Fitness > 0.9,IEI > 0.6),显著超出随机序列的典型范围。例如,2024年4月至5月在北美记录到的最高Fitness值(0.940,表2)和最大IEI值(0.563)远高于随机序列的平均值(分别为0.2046和0.1895),反映出对增强传播力和免疫逃逸能力的选择作用。

在各大洲中,北美和欧洲(测序数据丰富)的趋势显示,真实序列与其对应随机序列在Fitness和IEI分布之间存在尤为显著的差异。

总体而言,上述结果突显了全球六大洲S蛋白变体Fitness的演化趋势,表明其随时间推移呈上升趋势。

这些结果是由选择演化而非中性突变的随机效应所致。真实序列的分布显著偏离零模型预期,尤其是在数据丰富的区域(如全球整体和北美),表明选择压力(如免疫压力和环境因素)塑造了病毒的演化轨迹。这也凸显了本研究所提出的Fitness和免疫逃逸预测的统计稳健性。

3.2.6 SARS-CoV-2 S蛋白变体免疫逃逸能力的时间演化

平滑后的平均IEI随时间呈总体上升趋势,表明S蛋白变体的免疫逃逸能力逐步增强(图5A)。早期时间段IEI值较低,变异性大且存在大量异常值,提示早期变体的免疫逃逸能力具有多样性。随着时间推移,IEI值上升,变异性和异常数量减少,反映出较新变体具有更一致且更高的免疫逃逸能力。

在IEI曲线中,六大洲的轨迹总体呈上升趋势,但每个大陆在较短间隔内均出现一个或多个下降或停滞期。例如,北美IEI在2021年达到局部低谷(图5A)。

图5B展示了六大洲S蛋白变体免疫逃逸能力的演化趋势,显示IEI随时间上升,且近期变体的变异性降低。然而,2021年其他五个大陆的IEI也出现短期下降,与北美观察到的结果相似(图5B,补充图S11–S15)。

3.2.5 SARS-CoV-2 S蛋白变体Fitness的时间演化

从2020年1月至2024年5月共四年半期间的Fitness变化大致可分为三个阶段:第一阶段(2020年1月–2022年3月)、第二阶段(2022年3月–2023年3月)和第三阶段(2023年3月–2024年5月)(图4A)。

我们发现S蛋白变体的Fitness值随时间呈上升趋势。Fitness最低的病毒来自中国(祖先型,QZA85478.1,采集日期2020-02-23),其Fitness值为0.234(全球最低)。因此,所有样本的Fitness值均与中国野生型进行比较。在疫情初期,Fitness的变化率(曲线斜率)不高,Fitness值也较低。中期阶段,Fitness变化率急剧上升,这与病毒免疫逃逸能力增强相关(图5A)。后期阶段,Fitness值和免疫逃逸水平的增长速度均放缓,但已达到非常高的水平。

第一阶段存在许多Fitness值高于箱线图最大值的异常值,这是SARS-CoV-2早期暴发的显著特征。大量异常值表明病毒在暴发早期快速演化,积累了较多突变。突变越多,S蛋白的Fitness越高,导致许多变体的Fitness值显著超过该阶段的平均Fitness(图4A)。

第二阶段,超过箱线图最大值的异常值数量显著减少,而相当比例的异常值低于最小值。在整个阶段中,不仅低Fitness变体持续流行,高Fitness变体也更频繁出现。该阶段Fitness水平增长最快,表现为平滑平均Fitness曲线的陡峭斜率(图4A)。

第三阶段,低Fitness变体极为罕见,高于平均值的变体也较少,提示这是大流行末期的主要特征。此阶段尽管Fitness值较高,但平滑Fitness曲线的斜率显著下降。同时,高于均值的变体极少,表明病毒演化速率已减缓(图4A)。

其他五大洲的结果也观察到类似特征(图4B,补充图S6–S10)。

3.2.7 异常值影响的敏感性分析

对于北美两个异常值(WZD59850.1和WIJ15993.1,见图4A、5A),元数据验证显示其2020年初的采集日期与高突变数量(分别为66和42)不一致,可能存在记录错误。剔除这两个异常值后,分子钟速率仍为每年25.9223个替换(变化<0.0001%),北美平均Fitness和IEI值无显著变化(均<0.001%)。因此,这两个异常值的影响被显著稀释,未改变主要结论。

4 讨论

本回顾性研究阐明了2020年1月至2024年5月SARS-CoV-2刺突蛋白的动态演化,揭示了病毒适应性和免疫逃逸能力的显著转变。利用先进的蛋白质语言模型,我们的研究强调了基因突变在塑造COVID-19大流行轨迹中的关键作用,揭示了病毒适应人类免疫系统的复杂机制。

本研究基于六大洲及整体数据集构建了零模型,为评估SARS-CoV-2 S蛋白变体的Fitness和免疫逃逸趋势提供了基线。真实序列的适应性和免疫逃逸指数(IEI)显著偏离零模型预期(见第3.3节),表明适应性演化在增强病毒传播力和免疫逃逸能力中起关键作用。我们在零模型设计中纳入了氨基酸替换速率(每年25.9223个替换),并采用均匀随机突变生成方法,进一步证实观察到的演化趋势并非中性漂变的简单产物。Lee等人提出的基于实际变体频率分布的序列变异模型未来可被整合以优化零模型,更好地捕捉突变热点和变体竞争效应,从而深化对病毒演化机制的理解(44)。

地理和时间变异表明,病毒的适应性和免疫逃逸指数随环境条件和宿主群体遗传多样性而变化。这些变异可能反映不同的演化压力,例如高人口密度加速病毒突变和传播,而广泛的公共卫生干预可能限制这些变体的扩散(45, 46)。

与武汉发现的原始样本相比,北美前20名SARS-CoV-2变体表现出更高的适应性和免疫逃逸能力,表明病毒在人体宿主中已达到高度适应状态。然而,病毒演化速度已放缓,可能是因为在当前生物和社会环境中找到了相对稳定的适应状态。尽管如此,病毒是否会逐渐演化为类似季节性流感的季节性疾病,仍需对其长期行为模式及对公共健康的影响进行持续观察。因此,断言病毒将演化为季节性流感仍为时尚早,需进一步科学证据支持。

我们观察到北美IEI在2021年达到局部低谷。这可能由多种因素导致。首先,自2021年起,各国和卫生组织实施了多种公共卫生干预措施,如封锁和旅行限制(47, 48)。这些措施可能抑制了病毒传播,尤其是高免疫逃逸能力变体积累新突变以逃避免疫的能力(49)。其次,随着疫苗广泛接种,

此外,我们在研究期间(2024年4月1日至5月15日)发现,截至2024年初,北美S蛋白变体的适应性更高,表明该区域病毒可能正朝着更稳定的适应阶段过渡。这种稳定可能预示病毒向地方性流行阶段转变,可能呈现类似季节性流感的周期性暴发模式(46, 51, 52)。尽管本研究主要基于北美数据,我们认为其结论具有全球适用性。北美的高测序覆盖率使其成为观察SARS-CoV-2演化动态的坚实基础,例如JN.1谱系Fitness的升高。世界卫生组织(WHO,2024)报告称,截至2024年4月,全球超过94%的SARS-CoV-2序列源自JN.1(见https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines),这一趋势在2024年12月进一步得到确认,当时所有流行变体均为JN.1后代(见https://www.who.int/news/item/23-12-2024-statement-on-the-antigen-composition-of-covid-19-vaccines)。这种全球一致性,加上早期观察到的D614G和N439K等突变在多个区域传播的现象(2),表明北美观察到的演化趋势已在其他地区得到验证。此外,免疫选择压力的普遍性(如JN.1的免疫逃逸特性)与免疫驱动演化是全球现象的发现一致(2),进一步支持我们结论的全球相关性(见https://www.who.int/news/item/23-12-2024-statement-on-the-antigen-composition-of-covid-19-vaccines)。值得注意的是,尽管全球疫苗接种覆盖率持续上升,病毒的IEI仍在增加(49)。这突显了SARS-CoV-2在免疫压力下具有高度适应性,并能积累新突变以逃避免疫反应(45)。因此,持续的基因监测和疫苗策略的及时调整对于应对潜在暴发至关重要。

本研究采用蛋白质语言模型对SARS-CoV-2病毒的刺突蛋白进行了回顾性分析。方法学上,CoVFit利用历史数据开发深度学习模型,在此基础上,我们预测了历史刺突蛋白(S蛋白)序列的蛋白质Fitness和免疫逃逸能力。为回应潜在疑问,我们澄清:CoVFit模型的训练数据包含21,751个基因型-Fitness数据点,覆盖17个国家的12,914个基因型(19)。由于不同突变或变体组合可构成不同基因型,许多基因型包含重复突变。因此,用于训练CoVFit模型的变体数量估计在数百至数千之间,可通过CoVFit原始数据集精确量化。此外,本研究中分析的全球变体总数为160,892个,所用变体氨基酸序列均不含不确定的‘X’条目。因此,本回顾性分析中仅有约2%的数据与模型训练数据重叠。为确保样本完整性,我们未剔除这一极小部分重叠数据。因此,尽管回顾性研究可能包含模型训练期间使用的极小部分数据,但这不影响本研究得出主要结论。

北美有两个数据点在突变数量、Fitness值和IEI值方面异常高。其Fitness/IEI/突变值分别为0.944/0.571/66(WZD59850.1,JN.1)和0.712/0.404/42(WIJ15993.1,BA.4.6),采集日期分别为2020-01-20和2020-02-02。首先,我们推测这两个样本的采集日期可能存在记录错误。这是因为其他Fitness值大于0.9的样本均出现在2023年4月之后,而Fitness值高于0.7的其余样本则出现在2021年10月之后。

就WZD59850.1而言,若记录的采集日期正确,则意味着该样本在病毒暴发极早期短时间内经历了惊人的66次突变。该样本来源可能并非中国武汉,而可能代表美国本地2–3年内积累的突变,但需进一步系统发育分析验证此假设。

5 本研究局限性

尽管提供了全面分析,本研究仍存在若干需考虑的局限性。

首先,预测准确性很大程度上取决于所用数据质量。我们的数据集包含约250万条序列(约160,892个变体),可能因北美过度代表而存在偏倚,从而潜在影响对全球病毒演化模式的理解。例如,尽管我们通过敏感性分析处理了两个北美异常值(WZD59850.1和WIJ15993.1,见第2.7和3.2.7节),确认其对结果影响可忽略(分子钟速率变化<0.001%,Fitness和IEI均值变化<0.01%),但非北美地区(如非洲、大洋洲和南美)样本量极为有限(如非洲少于300个变体,见第2.4节),可能导致无法充分检测区域特异性演化趋势。

其次,尽管CoVFit蛋白质语言模型在预测Fitness和免疫逃逸能力方面取得显著进展,但其根本受限于训练数据的质量和多样性。该模型在来自17个国家的21,751个基因型-Fitness数据点上进行了微调(第2.4节),但训练序列中未充分捕获的病毒特性变化(如复杂突变互作(上位效应)或罕见变体效应)可能无法在模型预测中准确反映。此外,尽管CoVFit在1,506种冠状病毒上进行了预训练,其全面捕捉SARS-CoV-2特异性演化压力的能力仍可能受训练数据集代表性限制。

最后,尽管我们力求分析精确,免疫逃逸能力的计算预测无法完全替代实验室经验证。需持续将计算结果与实验数据比对,以确保预测的准确性和相关性。

这些局限性凸显了持续研究、数据收集和模型更新的重要性。未来可通过增加非北美地区的序列数据、提升模型捕捉突变互作的能力,以及整合体外实验验证以补充计算预测,从而增强计算工具在病毒学中的预测准确性和实用性。具体而言,未来研究可采用假病毒中和实验对预测的SARS-CoV-2变体Fitness和免疫逃逸能力进行实验验证,从而更稳健地评估模型预测。

作者贡献

SP:概念化、调查、撰写初稿。LL:撰写初稿、调查、方法论。LC:撰写初稿、审阅与编辑、资源。SS:撰写初稿、审阅与编辑、资源。MM:撰写初稿、审阅与编辑、资源。MB:撰写初稿、审阅与编辑、资源。JB:概念化、经费获取、监督、审阅与编辑。